Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cessation and reduction in alcohol consumption and misuse after psychedelic use
Albert Garcia‐Romeu, Alan K. Davis, Fire Erowid, et al.
Journal of Psychopharmacology (2019) Vol. 33, Iss. 9, pp. 1088-1101
Closed Access | Times Cited: 222

Showing 1-25 of 222 citing articles:

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder
Alan K. Davis, Frederick S. Barrett, Darrick G. May, et al.
JAMA Psychiatry (2020) Vol. 78, Iss. 5, pp. 481-481
Open Access | Times Cited: 924
The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects
David B. Yaden, Roland R. Griffiths
ACS Pharmacology & Translational Science (2020) Vol. 4, Iss. 2, pp. 568-572
Open Access | Times Cited: 361
Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety
Alan K. Davis, Frederick S. Barrett, Roland R. Griffiths
Journal of Contextual Behavioral Science (2019) Vol. 15, pp. 39-45
Open Access | Times Cited: 279
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies
Kristoffer A. A. Andersen, Robin Carhart‐Harris, David Nutt, et al.
Acta Psychiatrica Scandinavica (2020) Vol. 143, Iss. 2, pp. 101-118
Closed Access | Times Cited: 253
Long-term effects of psychedelic drugs: A systematic review
Jacob S. Aday, Cayla M. Mitzkovitz, Emily K. Bloesch, et al.
Neuroscience & Biobehavioral Reviews (2020) Vol. 113, pp. 179-189
Closed Access | Times Cited: 183
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 202-277
Open Access | Times Cited: 156
Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD
Alan K. Davis, Frederick S. Barrett, Sara So, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 4, pp. 437-446
Open Access | Times Cited: 129
Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience
Joseph Peill, Katie Trinci, Hannes Kettner, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 1, pp. 31-45
Open Access | Times Cited: 102
Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey
Albert Garcia‐Romeu, Alan K. Davis, Earth Erowid, et al.
Frontiers in Psychiatry (2020) Vol. 10
Open Access | Times Cited: 112
Ethics and ego dissolution: the case of psilocybin
William Smith, Dominic A. Sisti
Journal of Medical Ethics (2020) Vol. 47, Iss. 12, pp. 807-814
Open Access | Times Cited: 102
Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy
Natalie Gukasyan, Sandeep M. Nayak
Transcultural Psychiatry (2021) Vol. 59, Iss. 5, pp. 652-664
Closed Access | Times Cited: 101
Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes
Gabrielle Agin-Liebes, Trevor Forrest Haas, Rafael Lancelotta, et al.
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 2, pp. 543-552
Open Access | Times Cited: 95
Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation
Richard J. Zeifman, Anne Catherine Wagner, Ros Watts, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 84
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice
Ingmar Gorman, Elizabeth M. Nielson, Aja Molinar, et al.
Frontiers in Psychology (2021) Vol. 12
Open Access | Times Cited: 76
Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research
David A. Bender, David J. Hellerstein
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1907-1932
Closed Access | Times Cited: 64
Persisting Effects of Ayahuasca on Empathy, Creative Thinking, Decentering, Personality, and Well-Being
Maggie Kiraga, Natasha L. Mason, Malin V. Uthaug, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 62
Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review
Bruno Roméo, Marianne Hermand, Amélie Petillion, et al.
Journal of Psychiatric Research (2021) Vol. 137, pp. 273-282
Open Access | Times Cited: 59
Psychedelics and health behaviour change
Pedro J. Teixeira, Matthew W. Johnson, Christopher Timmermann, et al.
Journal of Psychopharmacology (2021) Vol. 36, Iss. 1, pp. 12-19
Open Access | Times Cited: 59
The therapeutic potential of psilocybin: a systematic review
Jan van Amsterdam, Wim van den Brink
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 6, pp. 833-840
Closed Access | Times Cited: 58
Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report
Drummond E-Wen McCulloch, Maria Zofia Grzywacz, Martin Bruun Madsen, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 54
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample
Victoria Amalie Nygart, Lis Marie Pommerencke, Eline Haijen, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 8, pp. 932-942
Open Access | Times Cited: 48
Psychedelic therapy in the treatment of addiction: the past, present and future
Rayyan Zafar, Maxim Siegel, Rebecca Harding, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 35
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020
Emma I Kopra, Jason Ferris, Adam Winstock, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 733-748
Open Access | Times Cited: 33
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, et al.
Neuropharmacology (2023) Vol. 226, pp. 109422-109422
Open Access | Times Cited: 32
Restructuring insight: An integrative review of insight in problem-solving, meditation, psychotherapy, delusions and psychedelics
Kadi Tulver, Karl Kristjan Kaup, Ruben Laukkonen, et al.
Consciousness and Cognition (2023) Vol. 110, pp. 103494-103494
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top